NKTR
Nektar Therapeutics Sets Sights on Revolutionizing Treatment Paradigms with Rezpegaldesleukin
San Francisco, CA - Nektar Therapeutics has made significant strides in 2025, and its momentum carries over into the new year. The company's latest financial results conference call provided a glimpse into the promising prospects of rezpegaldesleukin, a novel T-regulatory cell biologic being developed for atopic dermatitis, alopecia